Funding for this research was provided by:
National Institute on Aging (P01 AG046396, P01 AG036694, K24 AG035007, R21 AG054953)
Received: 26 October 2018
Accepted: 13 November 2018
First Online: 18 December 2018
Conflict of interest
: F.d’O.U., H.I.L.J., K.D.B., and M.R.P. have no disclosures to report. B.J.H. has served as a paid consultant for GE Healthcare. A.P.S. has served as a paid consultant for Biogen and Janssen. D.M.R. has served as a paid consultant for Eli Lilly, Janssen, Biogen and sits on the Scientific Advisory Board for Neurotrack. K.A.J. has served as paid consultant for Abbvie, AZtherapies, Biogen, GE Healthcare, Genetech, Genzyme, Isis, Janssen, Lundbeck, Merck, Novartis, Piramal, Roche, Eli Lilly, and Merck and Siemens Medical Solutions. He has served as a site principal investigator or co-investigator for Biogen, Eisai, Eli Lilly/Avid, Janssen, Lundbeck and Pfizer. R.A.S. has served as a paid consultant for Abbvie, Biogen, Bracket, GE, Genentech, Lundbeck, Merck, Otsuka, Pfizer, Roche and Sanofi. She has served as a co-investigator for Avid, Eli Lilly, and Janssen. She has spoken at symposia sponsored by Biogen, Eli Lilly, and Janssen. N.J.D. has received salary support from Eisai and Eli Lilly. She has served as a paid consultant to Avanir. Her spouse is employed by Alkermes. None of these disclosures are related to the content of this manuscript.